Zimmer Biomet Holdings, Inc. reported third quarter 2026 net sales of $2.063 billion, representing a 3.1% reported increase and a 3.7% increase on a constant currency basis. Diluted earnings per share were $1.00, down 13.8%, while adjusted diluted earnings per share were flat at $1.90. Following the broad-based performance, the company raised its full-year 2026 organic constant-currency revenue growth and adjusted EPS guidance.
Third quarter net sales reached $2.063 billion, up 3.1% on a reported basis.
Diluted earnings per share were $1.00, compared to $1.16 in the prior year period.
Adjusted diluted earnings per share were $1.90, matching the prior year period.
Full-year 2026 adjusted diluted EPS guidance was updated to a range of $8.50 to $8.60.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Zimmer Biomet's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$8.23B
+7.2%
$3.55
-19.9%
8.6%
FY2024
$7.68B
+3.8%
$4.43
-9.2%
11.8%
FY2023
$7.39B
+6.5%
$4.88
+343.6%
13.8%
FY2022
$6.94B
+1.6%
$1.10
-42.4%
3.3%
FY2021
$6.83B
+11.4%
$1.91
—
5.9%
Frequently asked questions
When is Zimmer Biomet's next earnings date?
Zimmer Biomet has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Zimmer Biomet earn last quarter?
For the quarter ended Sep 2026, Zimmer Biomet reported diluted EPS of $1.00 (-13.8% year over year) on revenue of $2.06B (+3.1%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.